MetLife Investment Management’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.65M | Buy |
84,660
+3,803
| +5% | +$156K | 0.02% | 681 |
|
|
2026
Q1 | $2.69M | Buy |
80,857
+423
| +0.5% | +$12.6K | 0.01% | 906 |
|
|
2025
Q4 | $2.4M | Sell |
80,434
-4,371
| -5% | -$143K | 0.01% | 988 |
|
|
2025
Q3 | $3.06M | Sell |
84,805
-1,730
| -2% | -$57K | 0.01% | 878 |
|
|
2025
Q2 | $3.11M | Buy |
86,535
+5,303
| +7% | +$197K | 0.02% | 782 |
|
|
2025
Q1 | $3.2M | Sell |
81,232
-3,128
| -4% | -$105K | 0.02% | 830 |
|
|
2024
Q4 | $2.54M | Buy |
84,360
+3,752
| +5% | +$108K | 0.01% | 922 |
|
|
2024
Q3 | $1.89M | Hold |
80,608
| – | – | 0.01% | 1049 |
|
|
2024
Q2 | $1.43M | Buy |
80,608
+8,286
| +11% | +$132K | 0.01% | 1145 |
|
|
2024
Q1 | $1.1M | Hold |
72,322
| – | – | 0.01% | 1241 |
|
|
2023
Q4 | $1.24M | Hold |
72,322
| – | – | 0.01% | 1190 |
|
|
2023
Q3 | $605K | Hold |
72,322
| – | – | ﹤0.01% | 1510 |
|
|
2023
Q2 | $1.8M | Buy |
72,322
+2,226
| +3% | +$57.5K | 0.01% | 973 |
|
|
2023
Q1 | $1.05M | Hold |
70,096
| – | – | 0.01% | 1200 |
|
|
2022
Q4 | $829K | Hold |
70,096
| – | – | 0.01% | 1308 |
|
|
2022
Q3 | $415K | Buy |
70,096
+6,093
| +10% | +$40K | ﹤0.01% | 1768 |
|
|
2022
Q2 | $272K | Sell |
64,003
-7,266
| -10% | -$45.4K | ﹤0.01% | 2091 |
|
|
2022
Q1 | $678K | Buy |
71,269
+26,443
| +59% | +$306K | ﹤0.01% | 1593 |
|
|
2021
Q4 | $852K | Hold |
44,826
| – | – | 0.01% | 1200 |
|
|
2021
Q3 | $1.49M | Hold |
44,826
| – | – | 0.01% | 963 |
|
|
2021
Q2 | $1.74M | Hold |
44,826
| – | – | 0.02% | 929 |
|
|
2021
Q1 | $2.16M | Sell |
44,826
-2,037
| -4% | -$97.9K | 0.02% | 835 |
|
|
2020
Q4 | $2.44M | Hold |
46,863
| – | – | 0.02% | 728 |
|
|
2020
Q3 | $1.25M | Buy |
46,863
+3,813
| +9% | +$87.7K | 0.01% | 933 |
|
|
2020
Q2 | $839K | Buy |
43,050
+5,331
| +14% | +$85.9K | 0.01% | 1099 |
|
|
2020
Q1 | $371K | Hold |
37,719
| – | – | 0.01% | 1369 |
|
|
2019
Q4 | $419K | Hold |
37,719
| – | – | ﹤0.01% | 1554 |
|
|
2019
Q3 | $212K | Hold |
37,719
| – | – | ﹤0.01% | 1913 |
|
|
2019
Q2 | $326K | Sell |
37,719
-47,133
| -56% | -$356K | ﹤0.01% | 1747 |
|
|
2019
Q1 | $682K | Buy |
84,852
+56,568
| +200% | +$306K | ﹤0.01% | 1887 |
|
|
2018
Q4 | $116K | Hold |
28,284
| – | – | ﹤0.01% | 2228 |
|
|
2018
Q3 | $158K | Hold |
28,284
| – | – | ﹤0.01% | 2212 |
|
|
2018
Q2 | $372K | Buy |
28,284
+7,358
| +35% | +$101K | ﹤0.01% | 1594 |
|
|
2018
Q1 | $297K | Hold |
20,926
| – | – | ﹤0.01% | 1680 |
|
|
2017
Q4 | $172K | Buy |
+20,926
| New | +$183K | ﹤0.01% | 2008 |
|
Other funds holding TGTX
SCM
CAM
MetLife Investment Management's TGTX Position: Q2 2026 in Review
MetLife Investment Management increased its TG Therapeutics (TGTX) stake by 4.7% in Q2 2026, buying an estimated $156K and bringing the position to 84,660 shares worth $4.65M. The position accounts for 0.02% of the portfolio, ranked #681.
MetLife Investment Management first reported a position in TGTX in Q4 2017 and has held it in 35 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- MetLife Investment Management held 84,660 shares of TG Therapeutics worth $4.65M as of Q2 2026.
- MetLife Investment Management bought 3,803 TG Therapeutics shares in Q2 2026, an estimated $156K.
- TG Therapeutics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #681 holding.
- MetLife Investment Management first reported a position in TG Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.